Investigational drug · Phase 2
BLEX 404 Liquid
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Myelodysplastic Syndrome (MDS), Triple Negative Breast Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "BLEX 404 Liquid"
First trial start
2027
Jan 1, 2027
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BLEX 404 Liquid", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myelodysplastic Syndrome (MDS)
- Triple Negative Breast Cancer
Approved drugs for the same conditions: Breast cancer · Myelodysplastic syndromes · Oncology · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "BLEX 404 Liquid" as an intervention, largest first.
BioLite, Inc.Industry
NCT02944955 · 52 participants (planned) · Start Jan 1, 2027 · Primary completion Dec 31, 2028
Drug: BLEX 404 Oral Liquid · For: Myelodysplastic Syndrome (MDS)
- Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.Not yet recruiting
BioLite, Inc.Industry
NCT02802423 · 44 participants (planned) · Start Jan 1, 2027 · Primary completion Apr 30, 2028
Drug: BLEX 404 Oral Liquid · For: Triple Negative Breast Cancer
- A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic CancerNot yet recruiting
Rgene CorporationIndustry
NCT03301805 · 40 participants (planned) · Start Jul 1, 2026 · Primary completion Apr 30, 2027
Drug: BLEX 404 · For: Pancreatic Cancer
- Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin TherapyNot yet recruiting
Rgene CorporationIndustry
NCT05764928 · 32 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 31, 2027
Drug: BLEX 404 · For: Nonsquamous Nonsmall Cell Neoplasm of Lung
Sites: Taipei, Taiwan
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Myelodysplastic Syndrome (MDS)
- CLN-049Phase 21 trial
Cullinan Therapeutics Inc. · Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), TP53-mutated MDS and AML
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.